Comparative Efficacy and Safety between Combination Therapy of Salmeterol/Fluticasone and Formoterol/Budesonide in Moderate Persistent Asthma
Authors/Creators
- 1. Assistant Professor, Department of Pharmacology, Pondicherry Institute of Medical Sciences, Kalapet, Pondicherry, Tamil Nadu, India
- 2. Associate Professor, Department of Pharmacology, NRI Institute of Medical Sciences, Vishakapatanam Andhra Pradesh, India
- 3. Associate Professor, Department of Pharmacology, Apollo Institute of Medical Sciences and Research, Chittoor, Andhra Pradesh, India
- 4. Emiretus Professor, Department of Respiratory Medicine, MNR Medical College, Hyderabad, India
Description
Background: Bronchial Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation causes an associated increase in airway hyper responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment. It is a heterogeneous pulmonary disorder characterized by recurrent episodes of cough, breathlessness, and wheezing, which may resolve spontaneously or after the use of bronchodilator medication. The global prevalence of asthma is anticipated to be approximately 4.5 per cent. There are about 334 million patients with asthma affecting all age groups across the world5. The prevalence of asthma has increased over time and an additional 100 million people worldwide are expected to develop asthma by the year 2025. Methods: The present prospective study has been done in Vizianagaram population in Maharajah`s institute of medical sciences to compare the efficacy and safety between combination therapy of salmeterol with fluticasone and formoterol with budesonide in moderate persistent asthma. Results & Conclusion: Formoterol budesonide combination is better in comparison to the salmeterol fluticasone combination considering the lesser no of exacerbations and bronchodilator effect, both salmeterol and formoterol being long-acting bronchodilators.
Abstract (English)
Background: Bronchial Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation causes an associated increase in airway hyper responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment. It is a heterogeneous pulmonary disorder characterized by recurrent episodes of cough, breathlessness, and wheezing, which may resolve spontaneously or after the use of bronchodilator medication. The global prevalence of asthma is anticipated to be approximately 4.5 per cent. There are about 334 million patients with asthma affecting all age groups across the world5. The prevalence of asthma has increased over time and an additional 100 million people worldwide are expected to develop asthma by the year 2025. Methods: The present prospective study has been done in Vizianagaram population in Maharajah`s institute of medical sciences to compare the efficacy and safety between combination therapy of salmeterol with fluticasone and formoterol with budesonide in moderate persistent asthma. Results & Conclusion: Formoterol budesonide combination is better in comparison to the salmeterol fluticasone combination considering the lesser no of exacerbations and bronchodilator effect, both salmeterol and formoterol being long-acting bronchodilators.
Files
IJTPR,Vol13,Issue7,Article19.pdf
Files
(697.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:82a9d85d84b3f5d327017cd80c079687
|
697.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-25
Software
References
- 1. O'Byrne P. GINA Executive Committee. Global strategy for asthma management and prevention. 2004. National Institutes of Health. 2. Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, et al. Guidelines for diagnosis and management of bronchial asthma L: Joint ICS/NCCP (I) recommendations. Lung India 2015;32(1): S3–42. 3. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59(5):469–78. 4. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health 2012,12:204. 5. The Global Asthma Report 2014. Auckland, New Zealand: Global Asthma Network. 2014. [accessed on February 16, 2015]. 6. Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, Jindal SK, et al. Prevalence and risk factors for bronchial asthma in Indian adults: a multicentre study. Indian J Chest Dis Allied Sci 2006;48(1):13–22. 7. Agarwal R, Denning DW, Chakrabarti A. Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS One. 2014; 9:0114745. 8. Murthy KJR, Sastry JG. Economic burden of asthma. Burden of disease in India. Background papers.[accessed on February 21, 2023]. 9. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. [accessed on February 16, 2015]. 10. Raphael GD, Lanier RQ, Baker J, Edwards L, Rickard K, Lincourt WR, A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. J Allergy Clin Immunol.1999;103;796-803. 11. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. the relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000; 161:9-16. 12. Global Initiative of Asthma. Global Strategy for Asthma Management and Prevention, 2016. 13. Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, Chaudhry K, Shah B. Indian study on epidemiology of asthma, respiratory symptoms, and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis. 2012 Sep;16(9):1270-7. 14. Ronald Dahl, Alexander Chuchalin, Dee Gor, Sally Yoxall, Raj Sharma, EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma Respiratory Medicine. 2006; 100: 1152–62. 15. Akamatsu T, Shirai T, Kato M, Yasui H, Hashimoto D, Fujisawa T, et al. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma. Pulm Pharmacol Ther. 2014;27(1):52- 6. 16. Ozgur Tunceli, Setareh A. Williams, David M. Kern, Hanaa Elhefni, Ned Pethick, Catrin Wessman, Siting Zhou, PhDa, Frank Trudo, Comparative Effectiveness of BudesonideFormoterol Combination and FluticasoneSalmeterol Combination for Asthma Management: A United States Retrospective Database Analysis. J Allergy clin immunol Pract. 2014; 2: 719–26. 17. Mario Cazzola, Clive P. Page, Luigino Calzetta and M. Gabriella Matera David R. Sibley, Pharmacology and Therapeutics of Bronchodilators, Pharmacological Reviews. 2012; 64 (3): 450-504.